Is there a future for gene therapy?

Neuromuscular Disorders

Volumn 9, Issue 2, 1999, Pages 102-107

  Howell, John McC ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Duchenne muscular dystrophy; Gene therapy; Golden retriever dog model

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; UTROPHIN; VIRUS VECTOR;

ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DOG; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; FUTUROLOGY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; MITOSIS; MYOBLAST; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DOGS; FORECASTING; GENE THERAPY; HUMANS; MUSCULAR DISEASES;

EID: 0032945429     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(98)00102-3     Document Type: Article

References (37)

1. Karpati G, Lochmuller H. The scope of gene therapy in humans: scientific, safety and ethical considerations. Neuromuscular Disord 1997;7:273-276.
2. Wolff JA. Naked DNA transport and expression in mammalian cells. Neuromuscular Disord 1997;7:314-318.
3. Human gene marker/therapy clinical protocols. Hum Gen Ther 1997; 8:2301-2338.
4. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felger PL. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
5. Acsadi G, Dickson G, Love DRM, Jani A, Walsh FS, Gurusinghe A, Wolff JA, Davies KE. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991;352:815-818.
6. Acsadi G, Lochmuller H, Jani A, Huard J, Massie B, Prescott S, Simoneau M, Karpati G. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gen Ther 1996;7:129-140.
7. McC Howell, J., Fletcher, S., Kakulas, B.A., O'Hara, M., Lochmuller, H., Karpati, G. Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. Neuromuscular Disord 7;325-328.
8. McC Howell J, Fletcher S, O'Hara A, Johnsen R, Lloyd F, Kakulas BA. Direct dystrophin and reporter gene transfer into dog muscle in vivo. Muscle Nerve 1998;21:159-165.
9. McC Howell J, Lochmuller H, O'Hara A, Fletcher S, Kakulas BA, Massie B, Nalbantoglu J, Karpati G. High-level dystrophin expression after adenovirus-mediated dystrophic minigene transfer to skeletal muscle of dystrophic dog: prolongation of expression with immunosuppression. Hum Gen Ther 1998;9:629-634.
10. Human trials set for DMD. Quest 1998; 5:9-10.
11. Van Deutekom JCT, Floyd SS, Booth DK, Oligino T, Kirsky D, Marconi P, Glorioso JC, Huard J. Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscular Disord 1998;8:135-148.
12. Lochmuller H, Petrof BJ, Pari G, Larochelle N, Dodelet V, Wang Q, Allen C, Prescott S, Massie B, Nalbantoglu J, Karpati G. Transient immunosuppression by FK506 permits a sustained high level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther 1996;3:706-716.
13. Kakulas BA. Problems and potential for gene therapy in Duchenne muscular dystrophy. Neuromuscular Disord 1997;7:319-324.
14. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995;2:107-115.
15. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b and E3 genes deleted. J Virol 1998;72:926-933y.
16. Ilan Y., Droguett G., Chowdhury N.R., Li Y., Sengupta K., Thummala N.R., Davidson A., Chowdhury J.R., Horwitz M.S. Proc Natl Acad Sci USA, 1997;94:2587-2592.
17. Douglas JT, Curiel DT. Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Neuromuscular Disord 1997;7:284-298.
18. Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC, Bellinger DA, Read MS, Walsh CE. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 1998;5:40-49.
19. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997;17:314-317.
20. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type I. J Virol 1998;72:811-816.
21. Feero W.G., Li S., Rosenblatt J.D., Sirianni N., Morgan J.E., Partridge T.A., Huang L., Hoffman E.P. Gene Ther 1997;4:664-674.
22. Dahlyat BI, Mayo SL. De novo protein design. Fully automated sequence selection. Science 1997;278:82-87.
23. Arancibia-Carcamo CV, Oral HB, Haskard DO, Larkin DF, George AJ. Lipoadenofection-mediated gene delivery to the corneal endothelium: prospects for modulating graft rejection. Transplantation 1998;65:62-67.
24. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, Chen Y. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997;100:1951-1957.
25. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., Sanes J.R. Cell 1997;90:729-738.
26. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997;90:717-727.
27. Deconinck N., Tinsley J., De Backer F., Fisher R., Kahn D., Phelps S., Davies K., Gillis J.M. Nat Med 1997;3:1216-1221.
28. Karpati G. Utrophin muscles in on the action. Nat Med 1997;3:22-23.
29. Gilbert R, Nalbanoglu J, Tinsley JM, Massie B, Davies KE, Karpati G. Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle. Biochem Biophys Res Commun 1998;242:244-247.
30. Gangopadhyay SB, Sherratt TG, Heckmatt JZ. Dystrophin in frame-shift deletion patients with Becker muscular dystrophy. Hum Genet 1992;51:562-570.
31. Wilton, S., Lloyd, F., Fletcher, S., Kole, R. Targeted dystrophin gene processing using antisense oligonucleotides. Neuromuscular Disord 1998;TO1:264.
32. Fanin M, Danieli GA, Vitiello L, Senter L, Angelini C. Prevalence of dystrophin positive fibres in 85 Duchenne muscular patients. Neuromuscular Disord 1992;2:41-45.
33. Mommaerts WFHM, Illingworth B, Pearson CM, Guillory RJ, Seraydarian K. A functional disorder of muscle associated with the absence of phosphorylase. Proc Natl Acad Sci USA 1959;45:791-797.
34. Schmid R, Hammaker L. Hereditary absence of muscle phosphorylase (McArdle's syndrome). N Engl J Med 1961;264:223-225.
35. Karpati G. Mitigation of deleterious effects of certain abnormal genes in immature skeletal muscle cells. Trends Neurosci 1984;7:360-361.
36. Crerar MM, Hudson JW, Matthews KE, David ES, Golding GB. Studies on the expression and evolution of the glycogen phosphorylase gene family in the rat. Genome 1988;30:582-590.
37. Tan P, Allen JG, Wilton SD, Akkari PA, Huxtable CR, Laing NG. A splice-site mutation causing ovine McArdle's disease. Neuromuscular Disord 1997;7:336-342.